SCHEMBL17758752

SCHEMBL17758752

OC(c1cccc(-n2cccn2)c1)c1cnc(Cl)s1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.39
LMNA P02545 1/20 0.37
F2RL1 P55085 1/20 0.37
ERCC1 P07992 1/20 0.36
ERCC4 Q92889 1/20 0.36
IDH1 O75874 1/20 0.35
GLS O94925 1/20 0.34
USP9X Q93008 1/20 0.34
MAPK1 P28482 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TBK1 Q9UHD2 2/20 0.34
KAT6A Q92794 1/20 0.33
RORC P51449 1/20 0.33
PI4KB Q9UBF8 1/20 0.33
IKBKE Q14164 1/20 0.33
GRM5 P41594 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
GRIN1 Q05586 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17758865 0.87 IDH1 (0.38) NOTUMLMNAERCC1ERCC4IDH1
SCHEMBL17758753 0.86 NOTUM (0.49) NOTUMF2RL1MAPK1KDM4EALDH1A1
SCHEMBL23352228 0.85 NOTUM (0.36) NOTUMLMNAF2RL1MAPK1KDM4E
SCHEMBL17758802 0.84 LMNA (0.39) NOTUMLMNAERCC1ERCC4IDH1
SCHEMBL20929258 0.83 POLB (0.36) NOTUMLMNAF2RL1MAPK1KDM4E
SCHEMBL23352193 0.79 LMNA (0.45) NOTUMLMNAF2RL1KDM4EALDH1A1
SCHEMBL23352192 0.78 USP9X (0.41) F2RL1USP9XKDM4EALDH1A1RORC
SCHEMBL23352236 0.78 USP9X (0.45) LMNAF2RL1USP9XKDM4EALDH1A1
SCHEMBL23352222 0.77 NOTUM (0.38) NOTUMLMNAF2RL1ERCC1ERCC4
SCHEMBL20929546 0.73 SLC6A3 (0.36) LMNAGLSKDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11459321-B2 Broad spectrum antiviral compositions and methods EVRYS BIO, LLC (US) 2022-10-04 US disclosed
US-11358961-B2 Anti-HCMV compositions and methods EVRYS BIO, LLC (US) 2022-06-14 US disclosed
US-20220135556-A1 ANTI-HCMV COMPOSITIONS AND METHODS EVRYS BIO, LLC (US) 2022-05-05 US disclosed
US-20210139475-A1 Broad Spectrum Antiviral Compositions and Methods EVRYS BIO, LLC (US) 2021-05-13 US disclosed
EP-3218373-B1 ANTI-HCMV COMPOSITIONS AND METHODS EVRYS BIO LLC (US) 2020-07-22 EP disclosed
US-20200140429-A1 ANTI-HCMV COMPOSITIONS AND METHODS EVRYS BIO, LLC (US) 2020-05-07 US disclosed
US-10556894-B2 Anti-HCMV compositions and methods EVRYS BIO, LLC (US) 2020-02-11 US disclosed
WO-2016077232-A2 ANTI-HCMV COMPOSITIONS AND METHODS FORGE LIFE SCIENCE, LLC (US) 2016-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11459321-B2 Broad spectrum antiviral compositions and methods IRF3, MAVS, ZC3HAV1 NOTUM 3929/4885LMNA 2718/4885F2RL1 4717/4885
US-11358961-B2 Anti-HCMV compositions and methods RPL35, RPL7, RPL5 NOTUM 3271/4885LMNA 1720/4885F2RL1 4715/4885
US-10556894-B2 Anti-HCMV compositions and methods RPL35, RPL7, RPL5 NOTUM 3271/4885LMNA 1720/4885F2RL1 4715/4885
US-20210139475-A1 Broad Spectrum Antiviral Compositions and Methods MAVS, IRF3, ZC3HAV1 NOTUM 3824/4885LMNA 3185/4885F2RL1 4466/4885
US-20200140429-A1 ANTI-HCMV COMPOSITIONS AND METHODS RPL35, RPL7, RPL5 NOTUM 3271/4885LMNA 1720/4885F2RL1 4715/4885
US-20220135556-A1 ANTI-HCMV COMPOSITIONS AND METHODS RPL35, RPL7, RPL5 NOTUM 3271/4885LMNA 1720/4885F2RL1 4715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.